DIAGNOS Inc. (TSXV:ADK)
Canada · Delayed Price · Currency is CAD | Market Cap | 41.71M +11.7% |
| Revenue (ttm) | 65.48K -36.9% |
| Net Income | -4.56M |
| EPS | -0.04 |
| Shares Out | 124.49M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 158,000 |
| Open | 0.3600 |
| Previous Close | 0.3500 |
| Day's Range | 0.3300 - 0.3600 |
| 52-Week Range | 0.1750 - 0.5300 |
| Beta | 0.08 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 20, 2026 |
About DIAGNOS
DIAGNOS Inc. provides software-based services for healthcare sector in Canada, the United States, Mexico, and internationally. It offers healthcare services through Computer Assisted Retina Analysis, a web-based software tool that assists healthcare professionals for the detection of diabetic retinopathy, as well as allows eye care specialists to visualize normal retinal landmarks and pathological changes. The company also provides various consulting services in the fields of data analysis and artificial intelligence. DIAGNOS Inc. was founded i... [Read more]
Financial Performance
In fiscal year 2026, DIAGNOS's revenue was 65,478, a decrease of -36.92% compared to the previous year's 103,797. Losses were -4.56 million, 6.27% more than in 2025.
Financial StatementsNews
DIAGNOS Accelerates Nationwide Deployment of Its CARA System Solution Licensed by Health Canada Following the Successful Installation of a First Group of Optometry Clinics
BROSSARD, Quebec, Oct. 20, 2026 (GLOBE NEWSWIRE) — Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of eye-related ...
DIAGNOS Provides an Update on Stock Warrants
BROSSARD, Quebec, Oct. 06, 2026 (GLOBE NEWSWIRE) — Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-rela...
DIAGNOS Provides an Update on Stock Warrants
BROSSARD, Quebec, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-rel...
DIAGNOS Advances Regulatory Strategy with US FDA Submission for CARA System
BROSSARD, Quebec, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-re...
DIAGNOS to Hold its Annual General Meeting of Shareholders on September 30, 2026
BROSSARD, Quebec, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of eye-relate...
DIAGNOS Receives Saudi FDA Medical Device License for CARA System, Bringing AI-Assisted Retinal Image Analysis to Saudi Arabia
BROSSARD, Quebec, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-rel...
DIAGNOS Receives Health Canada Medical Device Licence for CARA System, Bringing AI-Assisted Retinal Image Analysis to Canadian Optometrists
BROSSARD, Quebec, July 27, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-rel...
DIAGNOS Announces Shares for Debt Settlement
BROSSARD, Quebec, June 18, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-rel...
DIAGNOS Submits Modified and Updated Health Canada Licence Application for CARA System Platform
BROSSARD, Quebec, June 16, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of eye-related...
DIAGNOS Announces Grant of Stock Options and Adoption of Semi-Annual Reporting
BROSSARD, Quebec, June 12, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-rel...
Emerging Growth Research Releases Flash Report on DIAGNOS, Highlighting Regulatory Catalysts and Commercialization Potential for CARA AI Platform
BROSSARD, Quebec, June 05, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-rel...
DIAGNOS to Present at the Emerging Growth Conference on June 10, 2026
DIAGNOS invites individual and institutional investors, as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference. BROSSARD, Quebec, June 0...
DIAGNOS Announces Amendment to Convertible Debentures
BROSSARD, Quebec, May 13, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of critical hea...
DIAGNOS Provides an Update on Sales and Regulatory Activities for CARA
BROSSARD, Quebec, April 08, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of eye-relate...
DIAGNOS Successfully Completes the Renewal of US-FDA Medical Device Establishment Registration
BROSSARD, Quebec, April 01, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of eye-relate...
DIAGNOS Announces Amendments to Convertible Debentures and Stock Warrants
BROSSARD, Quebec, March 05, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of critical h...
DIAGNOS to present at Centurion One Capital 9th Annual Toronto Growth Conference
BROSSARD, Quebec, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of critical ey...
DIAGNOS and ÉTS Announce $1M+ Federal Investment to Propel Next-Generation Retinal AI Innovation
BROSSARD, Quebec, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of critical ey...
DIAGNOS Announces the Engagement of IBN
BROSSARD, Quebec, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues us...
Diagnos Announces Closing of Oversubscribed $4 Million Brokered Private Placement Led by Centurion One Capital
Not for distribution to United States newswire services or for dissemination in the United States. BROSSARD, Quebec, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Company”) (TSXV: ...
DIAGNOS to Extend Exercise Period of Stock Warrants Expiring on December 5, 2025
BROSSARD, Quebec, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues us...
DIAGNOS Announces $2.0 Million Brokered Private Placement Led by Centurion One Capital
Not for distribution to United States newswire services or for dissemination in the United States. BROSSARD, Quebec, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Company”) (TSXV: ...
DIAGNOS to Extend Exercise Period of Stock Warrants Expiring on November 9, 2025
BROSSARD, Quebec, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues us...
DIAGNOS to Present at the Centurion One Capital 3rd Annual Bahamas Summit
Brossard, Quebec--(Newsfile Corp. - October 15, 2025) - Diagnos Inc. (TSXV: ADK) (OTCQB: DGNOF) (FSE: 4D4A) ("DIAGNOS" or the "Corporation"), a pioneer in early detection of critical health issues usi...
DIAGNOS Announces Voting Results of Meeting of Shareholders
BROSSARD, Quebec, Sept. 25, 2025 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues u...